Loading
Micvotabart pelidotin is an experimental antibody-drug conjugate from Pyxis Oncology, in phase 1 trials for advanced solid tumours, with a focus on recurrent or metastatic head and neck squamous cell carcinoma.
Micvotabart pelidotin (PYX-201) is an antibody-drug conjugate (auristatin payload) from Pyxis Oncology. Targets the extradomain-B splice variant of fibronectin (EDB+FN) in the tissue around tumour cells and releases an auristatin payload there. Pyxis focuses it on recurrent or metastatic head and neck squamous cell carcinoma; it is in a phase 1 study alone (NCT05720117) and a phase 1/2 study in combination (NCT06795412), both in advanced solid tumours. Whether it works in people has not been established.
Targets the extradomain-B splice variant of fibronectin (EDB+FN) in the tissue around tumour cells and releases an auristatin payload there. Connects to FN1.
1.Micvotabart pelidotin's antibody arm binds FN1 on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Micvotabart pelidotin" OR ABSTRACT:"Micvotabart pelidotin" OR TITLE:"PYX-201" OR ABSTRACT:"PYX-201" OR TITLE:"MICVO" OR ABSTRACT:"MICVO") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Micvotabart pelidotin, not a curated reading list.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/